Reconfiguring the macrophage-centric intercellular network in pulmonary fibrosis: Emerging perspectives and therapeutic opportunities. (PubMed, Pharmacol Res) - Sep 8, 2026 - "Currently, only nintedanib, pirfenidone, and the novel phosphodiesterase 4B (PDE4B) inhibitor nerandomilast have received regulatory approval for clinical use. Emphasis is placed on reviewing the pharmacological mechanisms and recent advances in natural active compounds targeting this core cellular network to intervene in PF. The objective is to offer a theoretical foundation for a more comprehensive understanding of PF pathogenesis and to facilitate the optimization and innovation of anti-fibrotic therapeutic strategies."
Journal • Review • Fibrosis • Immunology • Inflammation • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases
|
|
Aoxin Zhang; Senyu Liu; Shangxuan Wang; Wenjuan Wang; Xiping Liu; Xuhui Zhang; Yujie Yang; Zhongbo Zhu
|